We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

Fund managers haven’t disclosed any holdings of PCRX yet.

PCRX Hedge Fund Activity: Q1 2026 in Review

241 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2026, worth a combined $986M — down 19% from $1.21B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of PCRX and 30 opened new positions — a net loss of 13 holders — while 82 trimmed existing stakes and 91 added.

The largest buyer was Empowered Funds, opening a new position worth an estimated $6.15M. The largest seller was Balyasny Asset Management, cutting an estimated $18.7M.

  • 241 institutional investors held Pacira BioSciences (PCRX) as of Q1 2026, down from 260 in Q4 2025.
  • Funds reported $986M of Pacira BioSciences stock for Q1 2026, down 19% quarter-over-quarter.
  • 30 funds opened new Pacira BioSciences positions in Q1 2026 and 43 closed out, a net change of -13 holders.
  • The largest Pacira BioSciences buyer in Q1 2026 was Empowered Funds, an estimated $6.15M added.
  • The largest Pacira BioSciences seller in Q1 2026 was Balyasny Asset Management, an estimated $18.7M sold.

Based on aggregated 13F filings for Q1 2026.